Athira Pharma, Inc. (ATHA)
After hours:
| Previous close | 2.0400 |
| Open | 2.0700 |
| Bid | 1.9700 x 100 |
| Ask | 2.0200 x 100 |
| Day's range | 2.0000 - 2.1000 |
| 52-week range | 1.3300 - 4.2980 |
| Volume | |
| Avg. volume | 354,932 |
| Market cap | 77.803M |
| Beta (5Y monthly) | 2.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.0900 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.42 |
Simply Wall St.One Athira Pharma Insider Raised Their Stake In The Previous Year
Viewing insider transactions for Athira Pharma, Inc.'s ( NASDAQ:ATHA ) over the last year, we see that insiders were...
GlobeNewswireAthira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercializationBOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 ye
- GlobeNewswire
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s diseaseBOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s di
